



PHARMACEUTICAL 2023











PHARMACEUTICAL 2023



Lyell Immunopharma Inc. Rank 54 of 446



The relative strengths and weaknesses of Lyell Immunopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lyell Immunopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 57% points. The greatest weakness of Lyell Immunopharma Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 7.2% points.

The company's Economic Capital Ratio, given in the ranking table, is 239%, being 196% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	651,295
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	37,028
Liabilities, Non-Current	67,281
Other Assets	163,243
Other Compr. Net Income	-5,976
Other Expenses	-4,754
Other Liabilities	0
Other Net Income	3,940
Other Revenues	84,683
Property and Equipment	123,023
Research and Development	159,188
Selling, General and Administrative Expense	117,307

Output Variable	Value in 1000 USD
Assets	937,561
Liabilities	104,309
Expenses	271,741
Revenues	84,683
Stockholders Equity	833,252
Net Income	-183,118
Comprehensive Net Income	-186,106
Economic Capital Ratio	239%

